PTPRC and acute myeloid leukemia: Gyurkocza et al. have recently published the result of a phase III SIERRA trial (NCT 02665065) comparing a targeted pretransplant regimen involving the anti-CD45 radio-conjugate 131 I- apamistamab with conventional conditioning in elderly patients (median age 64 years) with R/R AML.